Skip to main content

Highlights

  1. 1
    Nature immunology · 2024
    PMID: 39327500PMCID: PMC12636053DOISenior author58 citations
  2. 2
    Nature communications · 2021
    PMID: 34911956PMCID: PMC8674260DOISenior author284 citations
  3. 3
    Nature cancer · 2021
    PMID: 34917944PMCID: PMC8670735DOISenior author58 citations

Publications

116 publications

Active

15 grants
  • Sub-PI
    Therapeutic targeting of the tumor microenvironment in triple negative breast cancer patients at high risk of relapse and preclinical models of lung metastases
    National Cancer Institute · 2025–2030 · via Dartmouth-Hitchcock Medical Center
  • Co-I
    Discovery of a stem cell driving breast cancer spine metastases
    National Cancer Institute · 2024–2029
  • PI
    Therapeutic targeting of the tumor microenvironment in triple negative breast cancer patients at high risk of relapse and preclinical models of lung metastases
    U.S. Department of Defense · 2025–2029
    HT9425-25-1-0401
  • MPI
    Immunogenicity of lipid nanoparticles
    National Institute of Allergy and Infectious Diseases · 2024–2028 · via Cornell University - Ithaca
  • Co-I
    PICI Grant and Main Collaboration Agreement with Multiple Subprojects
    Parker Institute for Cancer Immunotherapy · 2024–2028
    PICI 235170-01
  • MPI
    ER stress-driven IRE1a-XBP1 signaling in lung cancer
    National Cancer Institute · 2023–2028
  • MPI
    Immunoregulatory role of lung-resident club cell factors in lung cancer
    National Cancer Institute · 2023–2028
  • MPI
    CAP-IT Center for LNP RNA Immunoprevention
    National Cancer Institute · 2022–2027
  • Co-I
    Dynamics of Immune Response in Irradiated Rectal Cancer
    National Cancer Institute · 2022–2027
  • PI
    Copper-Mediated Metabolic Reprogramming And ECM Alterations In TNBC Metastasis
    National Cancer Institute · 2021–2027
  • KP
    Elucidating the oncogenic role of EMSY in non-small cell lung cancer
    U.S. Department of Defense · 2024–2026
    HT9425-24-1-0019
  • KP
    Genetically engineered stem cell like T cells for the treatment of NSCLC
    American Association for Thoracic Surgery · 2024–2026
    AATS 235502-01
  • KP
    To study the EMT contributions in tumor metastasis and chemoresistance by using lineage tracing models
    National Cancer Institute · 2020–2026
  • KP
    Evaluating Lymph Node T Cell "Clonal Replacement" in a Phase II Trial of Neoadjuvant SBRT plus Cemiplimab versus Chemotherapy plus Cemiplimab in Resectable NSCLC
    WCM Sandra and Edward Meyer Cancer Center · 2025–2026
    MCC CTIF 250906-01
  • Co-I
    Targeting cytidine deaminase-induced chromosomal instability as a driver of metastasis in bladder cancer
    Starr Cancer Consortium · 2023–2025
    I16-0054
Completed grants (34)
  • KP
    Targeting APOBEC3A-induced chromosomal instability as a driver of metastasis in bladder cancer
    U.S. Department of Defense · 2023–2025
    HT9425-23-1-0790
  • KP
    Modulation of CD8+ T cell differentiation and anti-tumor immunity by metabolic manipulation
    National Center for Advancing Translational Sciences · 2024–2025
  • PI
    Targeting IL-1RAP to overcome EGFR-TKIs resistance in EGFR mutant NSCLC
    Cantargia AB · 2021–2025Contract
    SRA 213491-02
  • KP
    T cells selected from lymph node acquisition for adoptive cell treatment of solid tumors
    Daedalus Fund for Innovation (Weill Cornell) · 2024–2025BioPharma Alliance
    BP 242177-01
  • KP
    Characterizing T cell PD-1 response in the tumor draining lymph nodes of early-stage NSCLC patients
    International Association for the Study of Lung Cancer · 2023–2025
    IA 230418-01
  • MPI
    Intercepting progression from pre-invasive to invasive lung adenocarcinoma
    National Cancer Institute · 2019–2025· 2 renewals
  • MPI
    MSK Spore in Genomic Instability in Breast Cancer
    National Cancer Institute · 2024–2024 · via Memorial Sloan Kettering Cancer Center
  • KP
    Determine Mechanisms by Which Club Cell Factor/s Inhibit Myeloid-derived Suppressor Cells to Increase Efficacy of Immunotherapy in Lung Cancer
    PhRMA Foundation · 2023–2024
    PF 230234-01
  • KP
    Tumor draining lymph node immunomodulation to decrease recurrence in NSCLC
    LUNGevity Foundation · 2022–2024
    LF 2022-13
  • KP
    Targeting ART1, a novel immune checkpoint, for the treatment of lung cancer
    U.S. Department of Defense · 2019–2023
    W81XWH-19-1-0422
  • PI
    Examining the link between EZH2 and chromosomal instability in metastatic breast cancer
    Starr Cancer Consortium · 2021–2023
    SCC I14-0036
  • PI
    Addgene 704082
    Addgene, Inc. · 2022–2023
    Addgene 704082
  • PI
    Addgene 698979
    Addgene, Inc. · 2022–2023
    Addgene 698979
  • PI
    Targeting tumor intrinsic immunosuppressive mechanisms to enhance efficacy of immune checkpoint blockade in lung cancer
    U.S. Department of Defense · 2019–2022
    No publications yet
    W81XWH1910286
  • KP
    Clinical and Translational Science Center - KL2
    National Center for Advancing Translational Sciences · 2017–2022Career
  • Co-I
    The Role of RNA Methylation in Breast Cancer
    U.S. Department of Defense · 2019–2022
    No publications yet
    W81XWH1910118
  • KP
    Role of ER Stress-Driven IRE1a-XBP1 Signaling in Lung Cancer Pathogenesis
    National Cancer Institute · 2017–2021Fellowship
  • PI
    Targeting Neutrophil Protease-Mediated Degradation of Tsp-1 to Induce Metastatic Dormancy
    U.S. Department of Defense · 2016–2020
    W81XWH-16-1-0615
  • KP
    SPORE in Bladder Cancer
    National Cancer Institute · 2018–2020 · via Sloan-Kettering Institute for Cancer Research
  • KP
    The role of EZH2 histone methyltransferase in triple negative breast cancer metastasis
    PhRMA Foundation · 2018–2020Fellowship
    PF-180597
  • MPI
    Modeling Tumor-Stroma Crosstalk in Lung Cancer to Identify Targets for Therapy
    National Cancer Institute · 2015–2020 · via Methodist Hospital Research Institute
  • PI
    Identification and Targeting of Metastasis Suppressing miRNAs in Triple Negative Breast Cancer
    U.S. Department of Defense · 2016–2020
    W81XWH-16-1-0065
  • PI
    Targeting epigenetic regulator PRC2 as a therapy for established metastasis
    METAvivor Research and Support, Inc. · 2018–2020
    MRS 183299-02
  • KP
    ART1: A Novel Therapeutic Target For the Prevention of Metastases From Non-Small Cell Lung Cancer
    Free to Breathe · 2015–2019
    FTB 16010147-03
  • PI
    Inhibition of the IRE1alpha -XBP1 axis in lung cancer
    Quentis Therapeutics · 2018–2019Contract
    BP 184098-01
  • MPI
    Mechanisms of Copper Depletion in TNBC Metastasis - From Bedside to the Bench
    National Cancer Institute · 2017–2018 · via Cornell University - Ithaca
    U54CA210184-02
  • Sub-PI
    The Role of Endothelial Progenitor Cells in Tumor Growth and Metastasis
    National Cancer Institute · 2008–2016 · via Sloan-Kettering Institute for Cancer Research
  • MPI
    Center for Systematic Modeling of Cancer Development
    National Cancer Institute · 2012–2016 · via Methodist Hospital Research Institute· 2 renewals
  • PI
    Molecular Mechanisms of Tumor-Initiated Premetastatic Niche Formation in Lung Stroma
    National Cancer Institute · 2010–2015
  • KP
    Center on the Microenvironment and Metastasis
    National Cancer Institute · 2009–2015 · via Cornell University - Ithaca
  • Sub-PI
    Center for Transport Oncophysics: PSOC Outreach Pilot Project - Overcoming Barriers in Pleural Malignancies With Multistage Nanovectors
    National Cancer Institute · 2013–2014 · via Methodist Hospital Research Institute
  • KP
    Contribution of the Vascular Niche to the Hematopoietic Reconstitution
    National Heart, Lung, and Blood Institute · 2009–2013
  • Sub-PI
    Microfluidic Tumor Models to Analyze the Role of Physiochemical Cues in the Agniogenic Switch
    National Cancer Institute · 2009–2011 · via Cornell University - Ithaca
  • PI
    ANALYSIS OF Id GENE TARGETS IN TUMOR ENDOTHELIAL CELLS
    NCI · 2004–2010 · via NIH RePORTER

Clinical research

1 study
Completed & closed trials (1)
  • PI
    Targeting Tumor-Intrinsic Immunosuppressive Mechanisms to Enhance Efficacy of Immune Checkpoint Blockade in Lung Cancer
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2023)

Available technologies

News mentions

Show 4 more mentions
6 PhD students · 6 Postdocs